PCSK9 Inhibition: From Current Advances to Evolving Future - Liu, Chunping; Chen, Jing; Chen, Huiqi; Zhang, Tong; He, Dongyue; Luo, Qiyuan; Chi, Jiaxin; Hong, Zebin; Liao, Yizhong; Zhang, Shihui; Wu, Qizhe; Cen, Huan; et al. (Cells (Basel, Switzerland), 2022)
Keywords: Apolipoprotein E; Cardiovascular disease; Cardiovascular diseases; CD36 antigen; Cholesterol; clinical applications; Drug development; Forecasts and trends; Health aspects; Inflammation; Kexin; Lipoproteins; Lipoproteins (very low density); Liver; Low density lipoprotein; Low density lipoprotein receptors; Movement disorders; Neurodegenerative diseases; Nitric oxide; Pancreatic cancer; Parkinson's disease; PCSK9 inhibitors; Peptides; Proprotein convertases; Protease inhibitors; Proteins; R&D; Receptor density; Research & development; research status; Review; Scavenger receptors; security; Sepsis; Serine proteinase; Signal transduction; Statins; Subtilisin; Thrombosis; Toll-like receptors; China